Physician profile
Michael S Braun
NPI 1316996358
$9,082.17
in general payments reported to CMS, 2019-2025
28 companies · $665 in 2025
The $665 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,829 · 2020: $1,184 · 2021: $1,460 · 2022: $1,757 · 2023: $1,027 · 2024: $1,160 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,852.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,407.64 | 2019-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Lilly USA, LLC | $1,147.78 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $1,077.72 | 2019-2025 | Airsupra, Tezspire, Breztri |
| E.R. Squibb & Sons, L.L.C. | $950.41 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $673.85 | 2019-2024 | |
| Novo Nordisk INC | $521.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $463.19 | 2019-2025 | Evenity, Prolia, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $419.94 | 2021-2024 | |
| Amarin Pharma, INC. | $382.03 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $373.52 | 2020-2024 | Livalo, Seglentis |
| Glaxosmithkline, LLC. | $369.63 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $241.24 | 2019-2023 | Verquvo, Belsomra |
| Sanofi-Aventis U.S. LLC | $200.93 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $193.71 | 2019-2021 | |
| United Therapeutics Corporation | $125.00 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $96.91 | 2024 | Auvelity |
| Janssen Biotech, INC. | $80.45 | 2024-2025 | Tremfya, Stelara |
| Teva Pharmaceuticals USA, INC. | $71.67 | 2021-2025 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $51.44 | 2022-2023 | |
| Exact Sciences Corporation | $45.23 | 2025 | The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $41.69 | 2019 | |
| Esperion Therapeutics, INC. | $40.21 | 2020 | |
| Radius Health, INC. | $27.46 | 2020 | |
| Abbvie INC. | $19.44 | 2021 | |
| Horizon Therapeutics Plc | $17.19 | 2023 | Krystexxa |
| Boston Scientific Corporation | $16.87 | 2019 | |
| Astellas Pharma US INC | $13.18 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Braun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.